|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
PICK1 Genetic Variation and Cognitive Function in Patients with Schizophrenia.
|
28507309 |
2017 |
|
Schizophrenia
|
0.360 |
GeneticVariation
|
disease |
LHGDN |
We conclude that the common haplotypes and polymorphisms of the PICK1 gene identified thus far are unlikely to contribute to genetic susceptibility to schizophrenia in the Japanese population.
|
17367885 |
2007 |
|
Schizophrenia
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the common haplotypes and polymorphisms of the PICK1 gene identified thus far are unlikely to contribute to genetic susceptibility to schizophrenia in the Japanese population.
|
17367885 |
2007 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
We conclude that the common haplotypes and polymorphisms of the PICK1 gene identified thus far are unlikely to contribute to genetic susceptibility to schizophrenia in the Japanese population.
|
17367885 |
2007 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
Our findings implicating PICK1 as a susceptibility gene for SZ are consistent with a role for D-serine in the disease.
|
16314870 |
2006 |
|
Schizophrenia
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
In situ hybridization for AMPA-trafficking molecules showed decreased expression of PICK1 and increased expression of stargazin in DLPFC in schizophrenia, both restricted to large cells of cortical layer III.
|
16983646 |
2006 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
In situ hybridization for AMPA-trafficking molecules showed decreased expression of PICK1 and increased expression of stargazin in DLPFC in schizophrenia, both restricted to large cells of cortical layer III.
|
16983646 |
2006 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
Our findings implicating PICK1 as a susceptibility gene for SZ are consistent with a role for D-serine in the disease.
|
16314870 |
2006 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
LHGDN |
Our findings implicating PICK1 as a susceptibility gene for SZ are consistent with a role for D-serine in the disease.
|
16314870 |
2006 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
Here, we outline possible molecular mechanisms, discuss clinical case-studies that indicate an unexpected role of PICK1 in schizophrenia and discuss potential avenues for pharmacological manipulation of PICK1.
|
17011050 |
2006 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
BEFREE |
The positive association suggests that the PICK1 gene may play a role in the pathogenesis of schizophrenia.
|
15305146 |
2004 |
|
Schizophrenia
|
0.360 |
GeneticVariation
|
disease |
LHGDN |
The positive association suggests that the PICK1 gene may play a role in the pathogenesis of schizophrenia.
|
15305146 |
2004 |
|
Schizophrenia
|
0.360 |
Biomarker
|
disease |
PSYGENET |
The positive association suggests that the PICK1 gene may play a role in the pathogenesis of schizophrenia.
|
15305146 |
2004 |
|
Psychotic Disorders
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Psychotic Disorders
|
0.310 |
Biomarker
|
group |
PSYGENET |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Nonorganic psychosis
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Nonorganic psychosis
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Psychoses, Drug
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Psychoses, Substance-Induced
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Amphetamine-Related Disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Amphetamine Addiction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Amphetamine Abuse
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis.
|
17606663 |
2007 |
|
Neurodegenerative Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
We planned to block the PICK1-GluA2 protein-protein interaction with a small molecule inhibitor to stabilize surface AMPA receptors as a therapeutic possibility for neurodegenerative diseases.
|
29280296 |
2018 |
|
Neurodegenerative Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings demonstrate that it is possible to identify potent, selective PICK1-GluA2 inhibitors which may prove useful for treatment of neurodegenerative disorders.
|
30194389 |
2018 |
|
Neurodegenerative Disorders
|
0.030 |
Biomarker
|
group |
BEFREE |
Modulation of PICK1 could be targeted in other neurodegenerative diseases, as the toxicity of SCA1 and tau was also suppressed when PICK1 was down-regulated.
|
21949352 |
2012 |